Android app on Google Play

Goldman Sachs Downgrades Jazz Pharmaceuticals (JAZZ) to Neutral

December 16, 2013 7:07 AM EST Send to a Friend
Get Alerts JAZZ Hot Sheet
Price: $164.53 +0.80%

Rating Summary:
    22 Buy, 5 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 12 | Down: 21 | New: 21
Trade JAZZ Now!
Join SI Premium – FREE
Goldman Sachs downgraded Jazz Pharmaceuticals (NASDAQ: JAZZ) from Buy to Neutral with a price target of $123.00 (from $105.00).

For an analyst ratings summary and ratings history on Jazz Pharmaceuticals click here. For more ratings news on Jazz Pharmaceuticals click here.

Shares of Jazz Pharmaceuticals closed at $114.53 yesterday.




You May Also Be Interested In


Related Categories

Downgrades

Related Entities

Goldman Sachs

Add Your Comment